Retinitis Pigmentosa clinical trials

The registry lists 278 studies for Retinitis Pigmentosa across more than 10 countries. 72 are recruiting or about to start. 219 of them are mainly about Retinitis Pigmentosa (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Usher Syndromes too: 285 studies, 75 open.

Get an email when these change. Save the Retinitis Pigmentosa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 119
Recruiting: 49
Active, not recruiting: 34
Status unknown: 27
Terminated: 18
Not yet recruiting: 18

Phase

Phase 2: 75
Phase 1: 69
Phase 3: 21
Early Phase 1: 7
Phase 4: 1

Where

United States: 119
France: 40
Germany: 30
United Kingdom: 29
China: 17
Canada: 17

Who runs them

National Eye Institute (NEI) (13) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (9) · Johns Hopkins University (8) · Sheba Medical Center (6) · Second Sight Medical Products (6) · Ankara Universitesi Teknokent (5) · Okuvision GmbH (5) · MeiraGTx Ocular UK Ltd (5)

What is being tested here

Drugs under test in Retinitis Pigmentosa studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Minocycline	1	1	3
N-Acetylcysteinamide	1	1	1
NPI-001	1	1	1
Disulfiram	1	0	1
Ciliary Neurotrophic Factor	0	0	4
Retinol acetate	0	0	3
Platelet rich plasma	0	0	2
Acetylcysteine	0	1	2
Recombinant human nerve growth factor	0	0	2
Docosahexaenoic Acids	0	1	2

Coming up

10phase 3 studies under way

27studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Feb 2027A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa · Phase 3 · Ocugen
Jun 2027A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa · Phase 3 · MeiraGTx Ocular UK Ltd
Jul 2027Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II · Phase 3 · PT. Prodia Stem Cell Indonesia
Dec 2026Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) · jCyte, Inc
Dec 2026Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for Retinitis Pigmentosa · Nova Southeastern University
Dec 2026Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa · Peking University Third Hospital
Dec 2026Longitudinal Study of a Bionic Eye · Center for Eye Research Australia
Dec 2026BS01 in Patients With Retinitis Pigmentosa · Bionic Sight LLC
Dec 2026Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa · Qi Zhou
Dec 2026Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer · Sheba Medical Center

Who these studies take

Of the 49 Retinitis Pigmentosa studies recruiting now, 37 (76%) set no upper age limit and 7 (14%) stop at 75 or younger. 16 (33%) take children under 18. 0 (0%) are for women only and 2 (4%) for men only; 10 (20%) take healthy volunteers.

Recruiting studies that take each age, of 49
Age	Women	Men
10	12 (24%)	14 (29%)
18	46 (94%)	48 (98%)
30	47 (96%)	49 (100%)
40	47 (96%)	49 (100%)
50	47 (96%)	47 (96%)
65	46 (94%)	46 (94%)
75	42 (86%)	42 (86%)
85	41 (84%)	41 (84%)

Across all 278 studies, recruiting or not: 25% stop at 75 or younger and 16% at 65; 31% take children; <1% are for women only and 3% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Retinitis Pigmentosa studies take

Of 28 phase 1/2 interventional studies under Retinitis Pigmentosa, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1/2	53 mo22–92 · 28 studies	—	—
Interventional, no phase	42 mo21–154 · 30 studies	—	—
Observational	76 mo28–… · 48 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 14, 2026.

Newly registered1

Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)Oct 28, 2026NCT07901751

Studies

Recruiting first, then most recently updated. Showing 50 of 278. Browse all 278 → or search them.